CSL welcomes the Government’s plan to further develop onshore mRNA vaccine manufacturing capability.
While mRNA vaccine technology has been explored by researchers for many years, the COVID-19 pandemic has accelerated this technology from what was a promising science to a viable technology platform that can be produced at industrial scale.
CSL’s vaccine business – Seqirus – is one of the world’s leading influenza vaccine companies with Australia’s only onshore influenza manufacturing facility. For several years, Seqirus has been researching next-generation mRNA – self- amplifying mRNA – for influenza and pre-clinical results appear promising, with human clinical trials due to commence next year.